Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… presentations at Euretina Presentation title: Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber … Russell, MD, principal investigator of the ProQR Phase 1/2 clinicaltrial of sepofarsen Professor and Director of …
… Ophthalmology and has been involved in numerous global clinical trials for patients with inherited retinal diseases … IRD genes. He is currently the PI on seven different human clinical trials in Montreal, testing the safety and efficacy …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).
Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data